Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Outline of Final Research Achievements |
When Toll-like receptor (TLR)-mediated innate immune response was compared between Mucopolysaccharidosis (MPS)-specific cells and control iPS cells, zymosan or MALP2-mediated cytokine levels were significantly lower in MPS-specific iPS cells-derived dendritic cells compared to control iPS cells-derived dendritic cells. Then, when TLR-mediated innate immune response was compared between healthy neonates and healthy adults, immaturity of TLR-mediated immune response was disclosed to depend on cell types and TLR types in neonates, however zymosan provided comparable immune response between neonates and adults. Therefore, vaccine using zymosan as an adjuvant may play a key role in vaccine development for MPS children.
|